Venous thromboembolism and cancer: New issues for an old topic

Critical Reviews in Oncology/Hematology

Volumn 48, Issue 1, 2003, Pages 65-80

  Mandalà, Mario ^a   Ferretti, Gianluigi ^b   Cremonesi, Marco ^a   Cazzaniga, Marina ^a   Curigliano, Giuseppe ^c   Barni, Sandro ^a  

^a TREVIGLIO HOSPITAL   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Review; Solid tumours; Venous thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ASPARAGINASE; BLEOMYCIN; CANCER PROCOAGULANT; CARMUSTINE; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DALTEPARIN; DOXORUBICIN; ENOXAPARIN; FLUOROURACIL; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; METHOTREXATE; PREDNISOLONE; PROGESTERONE; TAMOXIFEN; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; VINCA ALKALOID; VINCRISTINE; WARFARIN;

BLEEDING; BLOOD CELL; BLOOD VESSEL CATHETERIZATION; BLOOD VESSEL INJURY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER SCREENING; CANCER SURGERY; CELL INTERACTION; CLINICAL TRIAL; CORRELATION ANALYSIS; DRUG EFFECT; DRUG EFFICACY; ENDOTHELIUM LESION; HUMAN; HYPERCOAGULABILITY; INCIDENCE; INTRAVENOUS CATHETER; MALIGNANT NEOPLASTIC DISEASE; OCCULT CANCER; PATHOPHYSIOLOGY; PROPHYLAXIS; QUALITY OF LIFE; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SOLID TUMOR; SURGICAL PATIENT; THROMBOEMBOLISM; TUMOR CELL; VASCULAR ACCESS; VENOUS THROMBOEMBOLISM;

EID: 0142247268     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(03)00041-6     Document Type: Review

References (158)

1. Trousseau A. Phlegmasia alba dolens. Clinique Medicale de l'Hotel-Dieu de Paris. 3:1865;94 The New Sydenham Society, London.
2. Rickles F.R., Levine M., Edwards R.L. Hemostatic alterations in cancer patients. Cancer Metast. Rev. 11:1992;237-248.
3. Green K.B., Silverstein R.L. Hypercoagulability in cancer. Hamatol. Oncol. Clin. North Am. 10:1996;499-530.
4. Folkman J. Tumor angiogenesis and tissue factor. Nat. Med. 2:1996;167-168.
5. Lieberman J.S., Borrero J., Urdanetta E., Wright I.S. Thrombophlebitis and cancer. J. Am. Med. Assoc. 177:1961;542-545.
6. Wright I.S. George E. Brown Memorial Lecture: pathogenesis and treatment of thrombosis. Circulation. 5:1952;161.
7. Nordstrom M., Lindblad B., Anderson H., Bergqvist D., Kjellstrom T. Deep venous thrombosis and occult malignancy. An epidemiological study. Br. Med. J. 308:1994;891-894.
8. Palumbo J.S., Kombrinck K.W., Drew A.F., et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood. 96:2000;3302-3309.
9. Lee Agnes Y.Y., Levine M. The thrombophilic state induced by therapeutic agents in the cancer patient. Semin. Thromb. Hemost. 25:1999;137-145.
10. Kwaan H.C. Cancer and hypercoagulability. Samama M.M. Hypercoagulable state: biological aspects and clinical management. 1966;243-245 CRC Press, Boca Raton, FL.
11. Sallah S., Wan J.Y., Nguyen N.P. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb. Haemost. 87:2002;575-579.
12. Sack G.H., Levin J., Bell W.R. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms. Medicine. 56:1977;1-37.
13. Barbui T., Finazzi G., Grassi A., Marchioli M. Thrombosis in cancer patients treated with hematopoietic growth factor - a meta-analysis. Thromb. Haemost. 75:1996;368-371.
14. Cornuz J., Pearson S.D., Creager M.A., Cook E.F., Goldman L. Importance of findings on the initial evaluation for cancer in patients with symptomatic idiopathic deep vein thrombosis. Ann. Intern. Med. 25:1996;785-793.
15. Gore J.M., Appelbaum J.S., Greene H.L., Dexter L., Dalen J.E. Occult cancer in patients with acute pulmonary embolism. Ann. Intern. Med. 96:1982;556-560.
16. Goldberg R.J., Seneff M., Gore J.M., et al. Occult malignant neoplasms in patients with deep venous thrombosis. Arch. Intern. Med. 147:1987;251-253.
17. Griffin M.R., Stanson A.S., Brown M.L., et al. Deep venous thrombosis and pulmonary embolism. Risk of subsequent malignant neoplasms. Arch. Intern. Med. 147:1987;1907-1911.
18. Sorensen H.T., Mellemkjaer L., Steffensen F.H., et al. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. New Engl. J. Med. 338:1998;1169-1173.
19. Baron J.A., Gridley G., Weiderpass E., Nyren O., Linet M. Venous thromboembolism and cancer. Lancet. 351:1998;1077-1080.
20. Aderka D., Brown A., Zelikovski A., Pinkhas J., et al. Idiopathic deep vein thrombosis in an apparently healthy patient as a premonitory sign of occult cancer. Cancer. 57:1986;1846-1849.
21. Monreal M., Salvador R., Soriano V., Sabria M. Cancer and deep venous thrombosis. Arch. Intern. Med. 148:1988;485.
22. Monreal M., Lafoz E., Casals A., et al. Occult cancer in patients with deep venous thrombosis. A systematic approach. Cancer. 67:1991;541-545.
23. Prandoni P., Lensing A.W., Buller H.R., et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. New Engl. J. Med. 327:1992;1128-1133.
24. Rance A., Emmerich J., Guedj C., Fiessinger J.N. Occult cancer in patients with bilateral thrombosis. Lancet. 350:1997;1448-1449.
25. Rajan R., Levine M., Gent M., et al. The occurrence of subsequent malignancy in patients with deep vein thrombosis. Results from a historical cohort study. Thromb. Haemost. 79:1998;19-22.
26. Hettiarachchi R.J.K., Prins M.H., Buller H.R., Prandoni P. Undiagnosed malignancy in patients with deep vein thrombosis: incidence, risk indicators, and diagnosis. Cancer. 83:1998;180-185.
27. Monreal M., Casals A., Boix J., Olazabal A., Montserrat E., Mundo M.R. Occult cancer in patients with acute pulmonary embolism. A prospective study. Chest. 103:1993;816-819.
28. Bastounis E.A., Karyiannakis A.J., Makri G.G., Alexious D., Papalambrous E.L. The incidence of occult cancer in patients with deep venous thrombosis: a prospective study. J. Intern. Med. 239:1996;153-156.
29. Ahmed Z., Mohyuddin Z. Deep vein thrombosis as a predictor of cancer. Angiology. 47:1996;261-265.
30. Monreal M., Fernandez-Liamazares J., Perandreu J. Occult cancer in deep vein thromboembolism: which patients, which cancers. Thromb. Haemost. 78:1997;1316-1318.
31. Schulman S., Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of anticoagulation trial. New Engl. J. Med. 342:2000;1953-1958.
32. Rickles F.R., Levine M. Epidemiology of thrombosis in cancer. Acta Hematol. 106:2001;6-12.
33. Falanga A., Rickles F.R. Molecular basis for the relationship between thrombosis and cancer. Thromb. Res. 102:2001;215-224.
34. Rao L.V.M. Tissue factor as a human procoagulant. Cancer Metast. Rev. 11:1992;249-266.
35. Callander N.S., Varki N., Rao L.V. Immunohistochemical identification of tissue factor in solid tumors. Cancer. 70:1992;1194-1201.
36. Kakkar A.K., Lemoine N.R., Scully M.F., TeBbutt S., Williamson R.C. Tissue factor expression correlates with histological grade in human pancreatic cancer. Br. J. Surg. 82:1995;1101-1104.
37. Hamada K., Kuratsu J., Saitoh Y., Takeshima H., Nishi T., Ushio Y. Expression of tissue factor correlates with grade in human glioma. Cancer. 77:1996;1877-1883.
38. Gordon S.G., Cross B.A. A factor X-activating cysteine protease from malignant tissue. J. Clin. Invest. 67:1981;1665.
39. Falanga A., Gordon S.G. Isolation and characterization of cancer procoagulant: a cysteine protease from malignant tissue. Biochemistry. 24:1985;5558-5567.
40. Gordon S.G., Mielicki W.P. Cancer procoagulant: a factor X activator, tumor marker and growth factor from malignant tissue. Blood Coag. Fibrinolys. 8:1997;73-86.
41. Donati M.B., Gambacorti-Passerini C., Casali B., et al. Cancer procoagulant in human tumor cells: evidence from melanoma patients. Cancer Res. 46:1986;6471-6474.
42. Zucchella M., Pacchiarini L., Tacconi F., et al. Different expression of procoagulant activity in human cancer cells cultured in vitro or in cells isolated from human tumor tissues. Thromb. Haemost. 69:1993;335-338.
43. Mueller B.M., Reisfeld R.A., Edgington T.S., Ruf W. Expresssion of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc. Natl. Acad. Sci. USA. 89:1992;11832-11836.
44. Falanga A., Iacoviello L., Evangelista V., et al. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia: corrective effect of all-trans-retinoic-acid. Blood. 86:1995;1072-1084.
45. De Stefano V., Teofili L., Sica S., et al. Effect of all-trans-retinoic- acid on procoagulant and fibrinolytic activities of cultured blast cells from patients with acute promyelocytic leukemia. Blood. 86:1995;3535-3541.
46. Barbui T., Finazzi G., Falanga A. The impact of all-transretinoic acid on the coagulopathy of acute promyelocytic leukemia. Blood. 91:1998;3093-3102.
47. Pearlstein E., Salk P.L., Yogeeswaran G., Karpatkin S. Correlation between spontaneous metastatic potential, platelet-aggregating activity of cell surface extracts, and cell surface sialylation in 10 metastatic-variant derivatives of a rat renal sarcoma cell line. Proc. Natl. Acad. Sci. USA. 77:1980;4336-4339.
48. Dvorak H.F. Abnormalities of hemostasis in malignant disease. Colman R.W., Hirsh J., Marder V.J., Saltzman E.W. Hemostasis and thombosis: basic principles and clinical practice. 1994;1238-1254 Lippincott, Philadelphia.
49. Piccioli A., Prandoni P., Ewenstein B.M., Goldhaber S.Z. Cancer and venous thromboembolism. Am. Heart J. 132:1996;850-855.
50. Levine M., Hirsh J., Gent M., et al. Double blind randomised trial of very low dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet. 343:1994;886-889.
51. Rajan R., Gafni A., Levine M., Hirsh J., Gent M. Very low dose warfarin prophylaxis to prevent thromboembolism in women with metastatic breast cancer receiving chemotherapy: an economic evaluation. J. Clin. Oncol. 13:1995;42-46.
52. Clahsen P.C., van de Velde C.J., Julien J.P., Floiras J.L., Mignolet F.Y. Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: a European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study. J. Clin. Oncol. 12:1994;1266-1271.
53. Goodnough L.T., Saito H., Manni A., Jones P.K., Pearson O.H. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients. Cancer. 54:1984;1264-1268.
54. Levine M.N., Gent M., Hirsh J., et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. New Engl. J. Med. 318:1988;404-407.
55. von Tempelhoff G.F., Dietrich M., Hommel G., Heilmann L. Blood coagulation during adjuvant epirubicin/cyclophosphamide chemotherapy in patients with primary operable breast cancer. J. Clin. Oncol. 14:1996;2560-2568.
56. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. New Engl. J. Med. 320:1989;491-496.
57. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl. Cancer Inst. 90:1998;1371-1388.
58. Fisher B., Costantino J.P., Redmond C., et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor positive tumors. New Engl. J. Med. 320:1989;479-484.
59. Cummings F.J., Gray R., Davis T.E., et al. Tamoxifen versus placebo: double blind adjuvant trial in elderly women with stage II breast cancer. NCI Monogr. 1:1986;119-123.
60. Pritchard K.I., Paterson A.H., Paul N.A., Zee B., Fine S., Pater J. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J. Clin. Oncol. 14:1996;2731-2737.
61. Saphner T., Tormey D.C., Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J. Clin. Oncol. 9:1991;286-294.
62. Weiss R.B., Tormey D.C., Holland J.F., Weinberg V.E. Venous thrombosis during multimodel treatment of primary breast carcinoma. Cancer Treat. Rep. 65:1981;677-679.
63. Tormey D.C., Gray R., Taylor S.G., et al. Postoperative chemotherapy and chemohormonal therapy in women with node positive breast cancer. NCI Monogr. 1:1986;75-80.
64. Wils J.A., Bliss J.M., Marty M., et al. Epirubicin plus tamoxifen versus tamoxifen alone in node-positive postmenopausal patients with breast cancer: a randomized trial of the International Collaborative Cancer Group. J. Clin. Oncol. 17:1999;1988-1998.
65. Fisher B., Dignam J., Wolmark N., et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J. Natl. Cancer Inst. 89:1997;1673-1682.
66. Rutqvist L.E., Mattsson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J. Natl. Cancer Inst. 85:1993;1398-1406.
67. McDonald C.C., Alexander F.E., Whyte B.W., Forrest A.P., Stewart H.J. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group. Br. Med. J. 311:1995;977-980.
68. Mannucci P.M., Bettega D., Charntarangkul V., et al. Effect of tamoxifen on measurements of hemostasis in healthy women. Arch. Intern. Med. 156:1996;1806-1810.
69. Weitz I.C., Israel V.K., Liebman H.A. Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden. Cancer. 79:1997;2024-2027.
70. Pannuti F., Martoni A., DiMarco A.R., et al. Prospective, randomized clinical trial of two different high dosages of medroxyprogesterone acetate (MAP) in the treatment of metastatic breast cancer. Eur. J. Cancer. 15:1979;593-601.
71. Tchekmedyian N.S., Tait N., Abrams J., et al. High dose megestrol acetate in the treatment of advanced breast cancer. Semin. Oncol. 15:1988;44-49.
72. Weijl N.I., Rutten M.F., Zwinderman A.H., et al. Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J. Clin. Oncol. 18:2000;2169-2178.
73. Levine M.N. Prevention of thrombotic disorders in cancer patients undergoing chemotherapy. Thromb. Haemost. 78:1997;133-136.
74. Levine M.N., Lee A.Y.Y. Treatment of venous thrombosis in cancer patients. Acta Haematol. 106:2001;81-87.
75. Freytes C.O. Indications and complications of intravenous devices for chemotherapy. Curr. Opin. Oncol. 12:2000;303-307.
76. Freytes C.O. Vascular access problems revisited: the Multinational Association of Supportive Care in Cancer (MASCC) experience. Support Care Cancer. 6:1998;13-19.
77. Bona R.D. Thrombotic complications of central venous catheters in cancer patients. Semin. Thromb. Hemost. 25:1999;147-155.
78. Prandoni P., Bernardi E. Upper extremity deep vein thrombosis. Curr. Opin. Pulmon. Med. 5:1999;222-226.
79. Mayo D.J., Cullinane A.M., Merryman P.K., Horne M.K. III. Serologic evidence of heparin sensitization in cancer patients receiving heparin flushes of venous access devices. Support Care Cancer. 7:1999;425-427.
80. Anderson A.J., Krasnow S.H., Boyer M.W., et al. Thrombosis: the major Hickman catheter complication in patients with solid tumor. Chest. 95:1989;71-75.
81. Horne M.K. III, May D.J., Alexander H.R., et al. Venographic surveillance of tunneled venous access devices in adult oncology patients. Ann. Surg. Oncol. 2:1995;174-178.
82. Balestreri L., De Cicco M., Matovic M., Coran F., Morassut S. Central venous catheter-related thrombosis in clinically asymptomatic oncologic patients: a phlebographic study. Eur. J. Radiol. 20:1995;108-111.
83. Gould J.R., Carloss H.W., Skinner W.L. Groshong catheter-associated subclavian venous thrombosis. Am. J. Med. 95:1993;419-423.
84. Schwarz R.E., Coit D.G., Groeger J.S. Transcutaneously tunneled central venous lines in cancer patients: an analysis of device-related morbidity factors based on prospective data collection. Ann. Surg. Oncol. 7:2000;441-449.
85. Schwarz R.E., Groeger J.S., Coit D.G. Subcutaneously implanted central venous access devices in cancer patients: a prospective analysis. Cancer. 79:1997;1635-1640.
86. Loughran S.C., Borzatta M. Peripherally inserted central catheters: a report of 2506 catheter days. J. Parenter. Enteral. Nutr. 19:1995;133-136.
87. Nightingale C.E., Norman A., Cunningham D., Young J., Webb A., Filshie J. A prospective analysis of 949 long-term central venous access catheters for ambulatory chemotherapy in patients with gastrointestinal malignancy. Eur. J. Cancer. 33:1997;398-403.
88. Eastridge B.J., Lefor A.T. Complications of indwelling venous access devices in cancer patients. J. Clin. Oncol. 13:1995;233-238.
89. Haire W.D., Lieberman R.P., Lund G.B., Edney J.A., Kessinger A., Armitage J.O. Thrombotic complications of silicone rubber catheters during autologous marrow and peripheral stem cell transplantation: prospective comparison of Hickman and Groshong catheters. Bone Marrow Transplant. 7:1991;57-59.
90. Puel V., Caudry M., Le Metayer P., et al. Superior vena cava thrombosis related to catheter malposition in cancer chemotherapy given through implanted ports. Cancer. 72:1993;2248-2252.
91. Lokich J.J., Becker B. Subclavian vein thrombosis in patients treated with infusion chemotherapy for advanced malignancy. Cancer. 52:1983;1586-1589.
92. De Cicco M., Matovic M., Balestreri L., et al. Central venous thrombosis: an early and frequent complication in cancer patients bearing long-term silastic catheter: a prospective study. Thromb. Res. 86:1997;101-113.
93. Lyon R.D., Griggs K.A., Johnson A.M., et al. Long-term follow-up of upper extremity implanted venous access devices in oncology patients. J. Vasc. Interv. Radiol. 10:1999;463-471.
94. Laurenzi L., Fimiani C., Faglieri N., et al. Complications with fully implantable venous access systems in oncologic patients. Tumori. 82:1996;232-236.
95. Bern M.M., Lokich J.J., Wallach S.R., et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomised prospective trial. Ann. Intern. Med. 112:1990;423-428.
96. Heaton D.C., Han D.Y., Inder A. Minidose (1 mg) warfarin as prophylaxis for central vein catheter thrombosis. Intern. Med. J. 32:2002;84-88.
97. Monreal M., Alastrue A., Rull M., et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices - prophylaxis with a low molecular weight heparin (fragmin). Thromb. Haemost. 75:1996;251-253.
98. Reichardt P, Kretzsxchmar A, Biakhov M, Irwin D, Slabber C, Miller L. A phase III randomized, double bind, placebo-controlled study evaluating the efficacy and safety of daily low-molecular-weigh-heparin (dalteparin sodium, fragmin) in preventing catheter-related complications (CRCs) in cancer patients with central catheters (CVCs) (abstract 1474). ASCO Proceed, 2002.
99. Vardy JL, Engelhardt K, Cox K, Jacquet J, Boyer MJ, Beale PJ. Subcutaneous central venous access port devices (CV APDs) inserted by interventional radiologists in cancer patients (abstract 2843). ASCO Proceed, 2002.
100. Carr K.M., Rabinowitz I. Physician compliance with warfarin prophylaxis for central venous catheters in patients with solid tumours. J. Clin. Oncol. 18:2000;3665-3667.
101. Scarfe M.A., Israel M.K. Possible drug interaction between warfarin and combination of levamisole and fluorouracil. Ann. Pharmacother. 28:1994;464-467.
102. Brown M.C. An adverse interaction between warfarin and 5-fluorouracil: a case report and review of the literature. Chemotherapy. 45:1999;392-395.
103. Levine M., Gent M., Hirsh J., et al. A comparison of low molecular weight heparin administered at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis. New Engl. J. Med. 334:1996;677-681.
104. Koopman M.M.W., Prandoni P., Piovella F., et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low molecular weight heparin administered at home. New Engl. J. Med. 334:1996;682-687.
105. Low molecular weight heparin in the treatment of patients with venous thromboembolism. New Engl. J. Med. 337:1997;657-662.
106. Harrison L., McGinnis J., Crowther M., Ginsberg J., Hirsh J. Assessment of outpatient treatment of deep vein thrombosis with low molecular weight heparin. Arch. Intern. Med. 158:1998;2001-2003.
107. Wells P.S., Kovacs M.J., Bormanis J., et al. Expanding eligibility for outpatient treatment of deep vein thrombosis and pulmonary embolism with low molecular weight heparin. Arch. Intern. Med. 158:1998;1809-1812.
108. Levine M., Raskob G., Landefeld C.S., Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest. 114:1998;511-523.
109. Krauth D., Holden A., Knapic N., et al. Safety and efficacy of long-term oral anticoagulation in cancer patients. Cancer. 59:1987;983-985.
110. Moore F.D., Osteen R.T., Karp D.D., et al. Anticoagulants, venous thromboembolism, and the cancer patient. Arch. Surg. 116:1981;405-407.
111. Prandoni P. Antithrombotic strategies in patients with cancer. Thromb. Haemost. 78:1997;141-144.
112. Bona R.D., Hickey A.D., Wallace D.M. Efficacy and safety of oral anticoagulation in patients with cancer. Thromb. Haemost. 8:1997;137-140.
113. Hutten B.A., Prins M.H., Gent M., Ginsberg J., Tijssen J., Buller H.R. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalised ratio. J. Clin. Oncol. 18:2000;3078-3083.
114. Gitter M.J., Jaeger T.M., Petterson T.M., et al. Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota. Mayo Clin. Proc. 70:1995;725-733.
115. Wester J.P., de Valk H.W., Nieuwenhuis H.K., et al. Risk factors for bleeding during treatment of acute venous thromboembolism. Thromb. Haemost. 76:1996;682-688.
116. Landefeld C.S., Cook E.F., Flatley M., et al. Identification and preliminary validation of predictors of major bleeding in hospitalised patients starting anticoagulant therapy. Am. J. Med. 82:1987;703-713.
117. Heit J.A., Mohr D.N., Silverstein M.D., Petterson T.M., O'Fallon W.M., Melton L.J. III. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch. Intern. Med. 160:2000;761-768.
118. Hansson P.O., Sorbo J., Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch. Intern. Med. 160:2000;769-774.
119. Woerner E.M., Rowe R.L. Trousseau's syndrome. Am. Fam. Phys. 38:1998;195-201.
120. Luk C., Wells P.S., Anderson D., Kovacs M.J. Extended outpatient therapy with low molecular weight heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy. Am. J. Med. 111:2001;270-273.
121. Meyer G., Marjanovic Z., Valcke J., et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch. Intern. Med. 162:2002;1729-1735.
122. Levine MN, Lee AY, Baker RI, Bowden C, Kakkar AK, Prins M. A randomized trial of long term dalteparin low molecular weight heparin (LMWH) versus oral anticoagulant (OA) therapy in cancer patients with venous thromboembolism (VTE) (abstract 2989) www.hematology.org.
123. Kakkar A.K., Williamson R.C.N. Prevention of venous thromboembolism in cancer patients. Semin. Thromb. Hemost. 25:1999;239-243.
124. Kakkar V.V., Howe C.T., Nicolaides A.N., Renney J.T., Clarke M.B. Deep vein thrombosis of the leg: is there a high risk group? Am. J. Surg. 120:1970;527-530.
125. Walsh J.J., Bonnar J., Wright F.W. A study of pulmonary embolism and deep leg-vein thrombosis after major gynaecological surgery using labelled fibrinogen-phlebography and lung scanning. J. Obstet. Gynaecol. Br. Commonw. 81:1974;311-316.
126. Rosenberg I.L., Evans M., Pollok A.V. Prophylaxis of postoperative leg vein thrombosis by low dose subcutaneous heparin or peroperative calf muscle stimulation: a controlled clinical trial. Br. Med. J. 1:1975;649.
127. Sue Ling H.M., Johnston D., McMahon M.J., Philips P.R., Davies J.A. Preoperative identification of patients at high risk of deep venous thrombosis after elective major abdominal surgery. Lancet. 1:1986;1173-1176.
128. Allan A., Williams J.T., Bolton J.P., Le Quesne L.P. The use of graduated compression stockings in the prevention of postoperative deep vein thrombosis. Br. J. Surg. 70:1983;172-174.
129. Dihydroergotamine-heparin prophylaxis of postoperative deep vein thrombosis. J. Am. Med. Assoc. 251:1984;2960-2966.
130. Huber O., Bounameaux H., Borst F., Rohner A. Postoperative pulmonary embolism after hospital discharge. An underestimated risk. Arch. Surg. 127:1992;310-313.
131. Clagett G.P., Andersonjr F.A., Heit J., Levine M.N., Wheeler H.B. Prevention of venous thromboembolism. Chest. 119:2001;132S-175S.
132. Clagett G.P., Reisch J.S. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Ann. Surg. 208:1988;227-240.
133. Gallus A.S., Salzman E.W., Hirsch J. Prevention of VTE. Colman R.W., Hirsh J., Marder V.J., et al. Hemostasis and thrombosis: basic principles and clinical practice. 3rd ed:1994;1331-1345 JB Lippincott, Philadelphia, PA.
134. Gallus A.S., Hirsh J., O'Brien S.E., McBride J.A., Tuttle R.J., Gent M. Prevention of venous thrombosis with small, subcutaneous doses of heparin. J. Am. Med. Assoc. 235:1976;1980-1982.
135. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. Br. J. Surg. 84:1997;1099-1103.
136. Kakkar V.V., Cohen A.T., Edmonson R.A., et al. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. The Thromboprophylaxis Collaborative Group. Lancet. 341:1993;259-265.
137. Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery. Br. J. Surg. 75:1988;1058-1063.
138. Bergqvist D., Burmark U.S., Flordal P.A., Frisell J., Hallbook T., Hedberg M. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients. Br. J. Surg. 82:1995;496-501.
139. Bergqvist D., Agnelli G., Cohen A.T., et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. New Engl. J. Med. 346:2002;975-980.
140. Nurmohamed M.T., van Riel A.M., Henkens C.M.A., et al. Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. Thromb. Haemost. 75:1996;223-238.
141. Agnelli G., Piovella F., Buoncristiani P., et al. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism in neurosurgery. New Engl. J. Med. 339:1996;80-85.
142. Bergqvist D., Burmark U.S., Friselli J., et al. Low molecular weight heparin once daily compared with conventional low-dose heparin twice daily. A prospective double-blind multicentre trial on prevention of postoperative thrombosis. Br. J. Surg. 73:1986;204-208.
143. Bergqvist D., Matzsch T., Friselli J., et al. Low molecular weight heparin given in the evening before surgery compared with conventional low-dose heparin in the prevention of thrombosis. Br. J. Surg. 75:1988;888-891.
144. Samama M., Bernard P., Bonnardot J.P., Combe-Tamzali S., Lanson Y., Tissot E. Low molecular weight heparin compared with unfractionated heparin in the prevention of postoperative thrombosis. Br. J. Surg. 75:1988;128-131.
145. Leizorovicz A., Picolet H., Peyrieux J.C., Boissel J.P. Prevention of postoperative deep vein thrombosis in general surgery: a multicenter double-blind study comparing two doses of logiparin and standard heparin. Br. J. Surg. 78:1991;412-416.
146. Boneu B. An international multicenter study: clivarin in the prevention of venous thromboembolism in patients undergoing general surgery. Blood Coag. Fibrinolys. 4:1993;S21-S22.
147. Ueno T., Toi M., Koike M., Nakamura S., Tominaga T. Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration. Br. J. Cancer. 83:2000;164-170.
148. Malmstrom P., Bendahl P.O., Boiesen P., Brunner N., Idvall I., Ferno M. South Sweden Breast Cancer Group. S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than the Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer. J. Clin. Oncol. 19:2001;2010-2019.
149. Zacharski L.R., Ornstein D.L. Heparin and cancer. Thromb. Haemost. 80:1998;10-23.
150. Zacharski L.R., Henderson W.G., Rickles F.R., et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer. 53:1984;2046-2052.
151. Wereldsma J.C., Bruggink E.D., Meijer W.S., Roukema J.A., van Putten W.L. Adjuvant portal liver infusion in colorectal cancer with 5-fluorouracil/ heparin versus urokinase versus control. Results of a prospective randomized clinical trial (colorectal adenocarcinoma trial I). Cancer. 65:1990;425-432.
152. Fielding L.P., Hittinger R., Grace R.H., Fry J.S. Randomised controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma. Lancet. 340:1992;502-526.
153. Kakkar AK, Kadziola Z, Williamson RCN, Levine MN, Low V, Lemoine NR. Low molecular weight heparin (LMWH) therapy and survival in advanced cancer (abstract 557). www.hematology.com.
154. Green D., Hull R.D., Brant R., Pineo G.F. Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet. 339:1992;1476.
155. Valentine K.A., Hull R.D., Pineo G.F. Low-molecular-weight heparin therapy and mortality. Semin. Thromb. Hemost. 23:1997;173-178.
156. Arnold D.M., Kahn S.R., Shrier I. Missed opportunities for prevention of venous thromboembolism: an evaluation of the use of thromboprophylaxis guidelines. Chest. 120:2001;1964-1971.
157. Monreal M., Ruiz J., Fraile M., et al. Prospective study on the usefulness of lung scan in patients with deep vein thrombosis of the lower limbs. Thromb. Haemost. 85:2001;771-774.
158. Monreal M., Lafoz E., Ruiz J., Valls R., Alastrue A. Upper-extremity deep venous thrombosis and pulmonary embolism. A prospective study. Chest. 99:1991;280-283.